Linked Life Data

12543673

Source:http://linkedlifedata.com/resource/pubmed/id/12543673

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2003-1-24
pubmed:abstractText
The bactericidal activities of ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, and gatifloxacin were tested in three models of rifampin-tolerant Mycobacterium tuberculosis persisters. Model 1 was a 100-day-old, unshaken, anaerobically adapted culture in which serial dilutions of the quinolones were incubated for 5 days and CFU counts were then done In models 2 and 3, 100 mg of rifampin/liter was added to the 100-day culture for 5 or 7 days to produce tolerant organisms that did not grow on plates; the rifampin was then washed off, fresh medium was added to allow recovery of growth on plates, and the culture was incubated for 7 days before CFU counts. In model 2, the quinolones were added after rifampin had been washed off, whereas in model 3 the quinolones were added to the cultures containing rifampin. In models 1 and 2, ciprofloxacin had the least bactericidal activity, ofloxacin and levofloxacin had greater activities, and moxifloxacin and gatifloxacin had the greatest activities. In model 3, ofloxacin had no detectable activity whereas moxifloxacin killed about log(10) 0.279 CFU of the persisters per ml at concentrations attainable in lesions; isoniazid had virtually no activity. These findings predict that ofloxacin will not be found to have effective sterilizing activity in clinical studies now planned whereas moxifloxacin will be able to shorten treatment.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/12543673-10837441, http://linkedlifedata.com/resource/pubmed/commentcorrection/12543673-10985648, http://linkedlifedata.com/resource/pubmed/commentcorrection/12543673-11053379, http://linkedlifedata.com/resource/pubmed/commentcorrection/12543673-11506908, http://linkedlifedata.com/resource/pubmed/commentcorrection/12543673-11530398, http://linkedlifedata.com/resource/pubmed/commentcorrection/12543673-11709328, http://linkedlifedata.com/resource/pubmed/commentcorrection/12543673-11897584, http://linkedlifedata.com/resource/pubmed/commentcorrection/12543673-1624388, http://linkedlifedata.com/resource/pubmed/commentcorrection/12543673-6774638, http://linkedlifedata.com/resource/pubmed/commentcorrection/12543673-8384811, http://linkedlifedata.com/resource/pubmed/commentcorrection/12543673-8675308, http://linkedlifedata.com/resource/pubmed/commentcorrection/12543673-9310011, http://linkedlifedata.com/resource/pubmed/commentcorrection/12543673-9687408
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
47
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
653-7
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.
pubmed:affiliation
Department of Medical Microbiology, St. George's Hospital Medical School, London. Biotherapies Ltd., Stockport, United Kingdom.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't